Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (September 2021)
31 slides from Cocrystal Pharma's investor presentation, Sep 14, 2021
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipelin
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets « Pandemic SARS-CoV-2, SARS-CoV-2 variants, and coronaviruses « Pandemic and seasonal influenza A ¢ Norovirus gastroenteritis Applying powertul, proprietary ‘ Drug candidates with clinically validated mechanisms of action
Slide 4: Investment Highlights
Investment Highlights e Targeting large, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing COVID-19 and influenza programs: ° Influenza A CC-42344, Phase 1 (oral administration) regulatory approval expected Q3 2021 e CO
Slide 5: Pipeline programs
Program COVID-19 COVID-19 (Licensed) COVID-19 Influenza A Influenza A/B Hepatitis C (HCV) Norovirus Gastroenteritis Oral Protease Inhibitor CDI-45205 Protease Inhibitor Replication Inhibitors CC-42344 PB2 Inhibitor Influenza A/B Inhibitor CC-31244 Pan-genotypic NS5B NNI Replication and Protease Inhi
Slide 6: Proprietary Drug Discovery Platform Technology for Direct-Acting-Antivirals
Proprietary Drug Discovery Platform Technology for Direct-Acting-Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select Drug Hit-to-lead Lead . . vr x-ray crystals binding pocket process optimization
Slide 7: Platform Provides Rapid, Efficient Drug Discovery and Development
Platform Provides Rapid, Efficient Drug Discovery and Development Traditional antiviral drug discovery and development can be long, costly and risky, with high rates of attrition 1 i Cocrystal’s technology platform provides potential for viable drug candidates at reduced costs and with shorter disco
Slide 8: Robust Antiviral Drug Discovery Founded by Proprietary Technology
Robust Antiviral Drug Discovery Founded by Proprietary Technology e Provide 3D structures of inhibitor protein complexes at near-atomic resolution with immediate insight to guide chemistry e Identify novel drug binding pockets e Design and develop broad-spectrum inhibitors with high barrier to drug
Slide 9: SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
Slide 10: Significant Need for Antivirals to Combat Coronavirus Infections
Significant Need for Antivirals to Combat Coronavirus Infections e There is no approved COVID-19 antiviral prophylactic treatment e There is no approved oral COVID-19 antiviral treatment e Coronaviruses constantly change through mutation’ e Multiple variants of COVID-19 have emerged! e The original
Slide 11: Novel COVID-19 Preclinical Leads
Novel COVID-19 Preclinical Leads Pe del RY Eee SARS-CoV-2 main protease (1.8 A) SARS-CoV-1 main protease (1.56 A) MERS-CoV main protease (1.9 A) Main (3CL) protease inhibitor e Binds to a highly conserved, essential residue (Cys145) of SARS-CoV-2 main (3CL) protease and other coronavirus main (3CL)
Slide 12: COVID-19: How Cocrystal Protease Inhibitor Will Work
COVID-19: How Cocrystal Protease Inhibitor Will Work SARS -CoV-2 Infected cell Membrane fusion Replication inhibitor ASSET Endocytosis Release Uncoating Non-structural Structural RNA Polyproteins proteins RNA proteins Translation Proteolysis Replication Translation Main (3CL) protease inhibitor 12 C
Slide 13: COVID-19 Program Status
COVID-19 Program Status e Oral broad-spectrum protease inhibitor e Expects to select preclinical lead by year end 2021 Initiated scale-up synthesis e Plan to initiate IND-enabling studies in H1 2022 e Oral broad-spectrum replication inhibitors e Lead discovery ongoing e Intranasal broad-spectrum pro
Slide 14: Influenza A Program
Influenza A Program
Slide 15: Influenza: A Major Global Health Concern
Influenza: A Major Global Health Concern * Worldwide: 1 billion cases", 3-5 million severe illnesses? and up to 650,000 deaths" annually ° U.S. statistics in flu season® (Oct. 1, 2019-April 4, 2020) 39-56 million cases e 18-26 million medical visits 410,000-740,000 hospitalizations e 24,000-62,000 d
Slide 16: Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication
Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication Trimeric RNA Polymerase Complex Nucleus PB1 Chimeric RNA Host pre-mRNA ( a, rn < , mnn-FESe “Cap snatching” Ons AAA i“ PB2 SoS, Endonucleolytic EOE “ee Boivin S et al. J. Biol. Chem. 2010;285:284
Slide 17: CC-42344: Pandemic and Seasonal Influenza A Therapeutic
CC-43244: Pandemic and Seasonal Influenza A Therapeutic * PB2 inhibitor binds to highly conserved pocket on replication enzyme Pandemic and seasonal influenza A PB2 crystals * Exhibits excellent broad-spectrum activity against CC-42344 pandemic and seasonal strains, and activity against known resist
Slide 18: Influenza A/B Program with Merck
Influenza A/B Program with € MERCK
Slide 19: Collaboration Validates Technology with Potential for Lucrative Returns
Collaboration Validates Technology with Potential for Lucrative Returns * Broad-spectrum, potent candidates developed to be active against seasonal, pandemic and existing drug-resistant influenza A and B strains * Announced exclusive worldwide license and collaboration with Merck in January 2019 Coc
Slide 20: Norovirus Gastroenteritis Program
Norovirus Gastroenteritis Program
Slide 21: Norovirus: Large Market with No Approved Treatments
Norovirus: Large Market with No Approved Treatments * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Major cause of gastrointestinal illness in closed and crowded environments including hospitals, nursing homes, childcare
Slide 22: Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors
Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors * Broad-spectrum norovirus protease and replication inhibitors are being developed * Ongoing drug discovery efforts * Oral protease inhibitor discovery using its proprietary drug discovery platform technology * Preclinical evalu
Slide 23: Hepatitis C Program
Hepatitis C Program
Slide 24: Hepatitis C: Increase in Rate of New Infections
Hepatitis C: Increase in Rate of New Infections An estimated 58 million people worldwide have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year’ An estimated 290,000 deaths occurred in 2019 worldwide due to hepatitis C, mostly from cirrhosis and hepatocell
Slide 25: CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy
CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy * Potential best-in-class HCV non-nucleoside inhibitor (NNI) with a strong profile * Broad-spectrum, potent NS5B polymerase inhibitor with high barrier to resistance * Effective against known NNI drug-resistant variants * Once-a-day oral
Slide 26: Seasoned Leadership
Seasoned Leadership Sam Lee, Ph.D. Interim Co-Chief Executive Officer & President 25+ years of anti-infective drug discovery research experience, including HCV and influenza antivirals; played key role in early development of phosphoinositide 3- A Zydelig Roger Kornberg, Ph.D. Professor 7 Chairman o
Slide 27: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NS5B (NNI)
Slide 28: Financial Snapshot
Financial Snapshot ~$121 Million 16.3 Million Average 3 month Market cap emis 99.5 Million Fully diluted shares Clean balance sheet No preferred shares No debt Only 243,000 warrants Cash runway beyond 2024 ‘Yahoo Finance “ C@CRYSTAL
Slide 29: Summary
Summary e Targeting large, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing COVID-19 and influenza programs: * Influenza A CC-42344, Phase 1 (oral administration) regulatory approval expected Q3 2021 * COVID-19 oral pr
Slide 30: Appendix
Appendix
Slide 31: CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy
CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy » Potential best-in-class HCV non-nucleoside inhibitor (NNI) with a strong profile » Broad-spectrum, potent NS5B polymerase inhibitor » Effective against known NNI drug-resistant variants * Orally administered; liver targeting Favorable
Cocrystal Pharma — Investor Presentation (September 2021) on 6ix